Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Vipshop Holdings Ltd - ADR trades at $13.94 (market cap $6.69B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.45% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VIPS | |
|---|---|---|
Market Cap | $39.89B | $6.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $20.68 |
52-Week Low | $278.09 | $12.92 |
Enterprise Value | $38.15B | $3.29B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Vipshop Holdings (VIPS) trades at $13.94, up 0.65% with a bullish technical signal despite mixed earnings history. The stock shows attractive valuation metrics with P/E of 6.36 and P/S of 0.45, supported by solid profitability including 18.43% ROE. Recent Q1 2026 earnings matched expectations while the company pursues growth through outlet store strategies.
The outlook remains positive with analyst consensus favoring Buy ratings (53.57%) and improving cash flow trends. Key risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds, but strong fundamentals and institutional support suggest potential for upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
